Short answer
Monopar Therapeutics (MNPR) filed an 8-K current report with the SEC on May 19, 2026 reporting Item 7.01 (Regulation FD Disclosure). Phase 2 ALXN1840-WD-204 results support ALXN1840’s potential to improve copper balance in Wilson disease.
Monopar Therapeutics 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Phase 2 ALXN1840-WD-204 results support ALXN1840’s potential to improve copper balance in Wilson disease
- Data presentation creates a clinical-development catalyst for Monopar’s Wilson disease program
- Press release dated May 19, 2026, furnished as Exhibit 99.1
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Monopar Therapeutics 8-K filings
Get the next MNPR 8-K as it lands
Follow MNPR for push alerts, or ask the research agent what this filing means.